Systemic Lupus Erythematosus - Articles

Sort by: Newest Most Comments Relevance

Systemic lupus erythematosus (SLE) by Ahmad.H Posted Fri 03 Dec 2010 12:00am SLE is a chronic disease that causes inflammation of connective tissue. It is a multisystem autoimmune inflammatory disease. SLE is the commonest and the most serious type of lupus. What causes SLE ? SLE is believed to be an autoimmune disease, which means that the body's immune system produce antibodies that attacks the own ... Read on »

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE) by Duane P. Patient Expert

Posted Mon 31 Aug 2009 10:08pm

1 Comment UCB and Immunomedics announced on Friday top-line results from a Phase IIb clinical study which compared the effect of the drug candidate epratuzumab to placebo in people with systemic lupus. The data showed that the 12-week dose response and the dose frequency study of epratuzumab in patients with moderate to severe active lupus demonstrated a cli ... Read on »

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE) by Wick D. Posted Mon 31 Aug 2009 6:58am UCB and Immunomedics announced on Friday top-line results from a Phase IIb clinical study which compared the effect of the drug candidate epratuzumab to placebo in people with systemic lupus. The data showed that the 12-week dose response and the dose frequency study of epratuzumab in patients with moderate to severe active lupus demonstrated a cli ... Read on »

OxLDL/β2GPI Complexes and Autoantibodies in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, and Antiphospho by Jan Posted Fri 11 Sep 2009 4:56pm By LUIS R. LOPEZ and Colleague Abstract: Oxidized low-density lipoprotein (oxLDL) interacts with β2GPI, forming oxLDL/β2GPI complexes. Autoimmune vascular inflammation (and oxidative stress ) may promote the formation of these complexes. The coexistence of oxLDL/β2GPI complexes with autoantibodies to these complexes su ... Read on »

OxLDL/β2GPI Complexes and Autoantibodies in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, and Antiphospho by Jan Posted Fri 11 Sep 2009 4:56pm By LUIS R. LOPEZ and Colleague Abstract: Oxidized low-density lipoprotein (oxLDL) interacts with β2GPI, forming oxLDL/β2GPI complexes. Autoimmune vascular inflammation (and oxidative stress) may promote the formation of these complexes. The coexistence of oxLDL/β2GPI complexes with autoantibodies to these complexes suggest ... Read on »

Sicca symptoms in Thai patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma: a comparison with age-m by Jan Posted Fri 11 Sep 2009 4:58pm Research by Wangkaew S. and Colleague. This study was performed to determine the prevalence of ocular and oral sicca symptoms in Thai patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and scleroderma (Scl). The ocular symptoms and sign (the Schirmer's 1 test) and the oral sicca symptoms and sign (the Saxon's ... Read on »

Anxiety News: Anxiety And Depression Lower Quality Of Life In Majority Of Systemic Lupus Erythematosus Patients by Katie G. Healthy Living Professional

Posted Wed 17 Jun 2009 6:31pm Anxiety And Depression Lower Quality Of Life In Majority Of Systemic Lupus Erythematosus Patients ScienceDaily (June 12, 2009) — 92.8% of patients with systemic lupus erythematosus (SLE) suffer anxiety and depression which significantly affects both their physical and emotional quality of life (QoL), according to the results of a new study pr ... Read on »

New Data Shows Epratuzumab Provided Significant Efficacy for Patients with Moderate to Severe Systemic Lupus Erythematosus by Wick D. Posted Wed 16 Jun 2010 12:10pm UCB and Immunomedics Inc. announced today that a new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Findings demonstrate that in a patient population with predominantly severe disease activity, epratuzumab is improving ... Read on »

New Data Shows Epratuzumab Provided Significant Efficacy for Patients with Moderate to Severe Systemic Lupus Erythematosus by Duane P. Patient Expert

Posted Wed 16 Jun 2010 9:02am UCB and Immunomedics Inc. announced today that a new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Findings demonstrate that in a patient population with predominantly severe disease activity, epratuzumab is improving patients' ... Read on »

Systemic sclerosis (scleroderma) associated with discoid lupus erythematosus. by Jan Posted Sun 29 Aug 2010 12:00am Six patients with systemic sclerosis (SS) and discoid lupus erythematosus (DLE) were studied to determine whether such cases have some common clinical and laboratory findings. DLE preceded SS in all cases. Three patients had diffuse scleroderma with lung and esophagus involvements and the others limited scleroderma. Three patients had an ... Read on »